Cargando…
Human embryonic stem cell-derived endothelial cell product injection attenuates cardiac remodeling in myocardial infarction
BACKGROUND: Mechanisms contributing to tissue remodeling of the infarcted heart following cell-based therapy remain elusive. While cell-based interventions have the potential to influence the cardiac healing process, there is little direct evidence of preservation of functional myocardium. AIM: The...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9588936/ https://www.ncbi.nlm.nih.gov/pubmed/36299872 http://dx.doi.org/10.3389/fcvm.2022.953211 |
_version_ | 1784814184995749888 |
---|---|
author | Spiroski, Ana-Mishel McCracken, Ian R. Thomson, Adrian Magalhaes-Pinto, Marlene Lalwani, Mukesh K. Newton, Kathryn J. Miller, Eileen Bénézech, Cecile Hadoke, Patrick Brittan, Mairi Mountford, Joanne C. Beqqali, Abdelaziz Gray, Gillian A. Baker, Andrew H. |
author_facet | Spiroski, Ana-Mishel McCracken, Ian R. Thomson, Adrian Magalhaes-Pinto, Marlene Lalwani, Mukesh K. Newton, Kathryn J. Miller, Eileen Bénézech, Cecile Hadoke, Patrick Brittan, Mairi Mountford, Joanne C. Beqqali, Abdelaziz Gray, Gillian A. Baker, Andrew H. |
author_sort | Spiroski, Ana-Mishel |
collection | PubMed |
description | BACKGROUND: Mechanisms contributing to tissue remodeling of the infarcted heart following cell-based therapy remain elusive. While cell-based interventions have the potential to influence the cardiac healing process, there is little direct evidence of preservation of functional myocardium. AIM: The aim of the study was to investigate tissue remodeling in the infarcted heart following human embryonic stem cell-derived endothelial cell product (hESC-ECP) therapy. MATERIALS AND METHODS: Following coronary artery ligation (CAL) to induce cardiac ischemia, we investigated infarct size at 1 day post-injection in media-injected controls (CALM, n = 11), hESC-ECP-injected mice (CALC, n = 10), and dead hESC-ECP-injected mice (CALD, n = 6); echocardiography-based functional outcomes 14 days post-injection in experimental (CALM, n = 13; CALC, n = 17) and SHAM surgical mice (n = 4); and mature infarct size (CALM and CALC, both n = 6). We investigated ligand–receptor interactions (LRIs) in hESC-ECP cell populations, incorporating a publicly available C57BL/6J mouse cardiomyocyte-free scRNAseq dataset with naive, 1 day, and 3 days post-CAL hearts. RESULTS: Human embryonic stem cell-derived endothelial cell product injection reduces the infarct area (CALM: 54.5 ± 5.0%, CALC: 21.3 ± 4.9%), and end-diastolic (CALM: 87.8 ± 8.9 uL, CALC: 63.3 ± 2.7 uL) and end-systolic ventricular volume (CALM: 56.4 ± 9.3 uL, CALC: 33.7 ± 2.6 uL). LRI analyses indicate an alternative immunomodulatory effect mediated via viable hESC-ECP-resident signaling. CONCLUSION: Delivery of the live hESC-ECP following CAL modulates the wound healing response during acute pathological remodeling, reducing infarct area, and preserving functional myocardium in this relatively acute model. Potential intrinsic myocardial cellular/hESC-ECP interactions indicate that discreet immunomodulation could provide novel therapeutic avenues to improve cardiac outcomes following myocardial infarction. |
format | Online Article Text |
id | pubmed-9588936 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-95889362022-10-25 Human embryonic stem cell-derived endothelial cell product injection attenuates cardiac remodeling in myocardial infarction Spiroski, Ana-Mishel McCracken, Ian R. Thomson, Adrian Magalhaes-Pinto, Marlene Lalwani, Mukesh K. Newton, Kathryn J. Miller, Eileen Bénézech, Cecile Hadoke, Patrick Brittan, Mairi Mountford, Joanne C. Beqqali, Abdelaziz Gray, Gillian A. Baker, Andrew H. Front Cardiovasc Med Cardiovascular Medicine BACKGROUND: Mechanisms contributing to tissue remodeling of the infarcted heart following cell-based therapy remain elusive. While cell-based interventions have the potential to influence the cardiac healing process, there is little direct evidence of preservation of functional myocardium. AIM: The aim of the study was to investigate tissue remodeling in the infarcted heart following human embryonic stem cell-derived endothelial cell product (hESC-ECP) therapy. MATERIALS AND METHODS: Following coronary artery ligation (CAL) to induce cardiac ischemia, we investigated infarct size at 1 day post-injection in media-injected controls (CALM, n = 11), hESC-ECP-injected mice (CALC, n = 10), and dead hESC-ECP-injected mice (CALD, n = 6); echocardiography-based functional outcomes 14 days post-injection in experimental (CALM, n = 13; CALC, n = 17) and SHAM surgical mice (n = 4); and mature infarct size (CALM and CALC, both n = 6). We investigated ligand–receptor interactions (LRIs) in hESC-ECP cell populations, incorporating a publicly available C57BL/6J mouse cardiomyocyte-free scRNAseq dataset with naive, 1 day, and 3 days post-CAL hearts. RESULTS: Human embryonic stem cell-derived endothelial cell product injection reduces the infarct area (CALM: 54.5 ± 5.0%, CALC: 21.3 ± 4.9%), and end-diastolic (CALM: 87.8 ± 8.9 uL, CALC: 63.3 ± 2.7 uL) and end-systolic ventricular volume (CALM: 56.4 ± 9.3 uL, CALC: 33.7 ± 2.6 uL). LRI analyses indicate an alternative immunomodulatory effect mediated via viable hESC-ECP-resident signaling. CONCLUSION: Delivery of the live hESC-ECP following CAL modulates the wound healing response during acute pathological remodeling, reducing infarct area, and preserving functional myocardium in this relatively acute model. Potential intrinsic myocardial cellular/hESC-ECP interactions indicate that discreet immunomodulation could provide novel therapeutic avenues to improve cardiac outcomes following myocardial infarction. Frontiers Media S.A. 2022-10-10 /pmc/articles/PMC9588936/ /pubmed/36299872 http://dx.doi.org/10.3389/fcvm.2022.953211 Text en Copyright © 2022 Spiroski, McCracken, Thomson, Magalhaes-Pinto, Lalwani, Newton, Miller, Bénézech, Hadoke, Brittan, Mountford, Beqqali, Gray and Baker. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Cardiovascular Medicine Spiroski, Ana-Mishel McCracken, Ian R. Thomson, Adrian Magalhaes-Pinto, Marlene Lalwani, Mukesh K. Newton, Kathryn J. Miller, Eileen Bénézech, Cecile Hadoke, Patrick Brittan, Mairi Mountford, Joanne C. Beqqali, Abdelaziz Gray, Gillian A. Baker, Andrew H. Human embryonic stem cell-derived endothelial cell product injection attenuates cardiac remodeling in myocardial infarction |
title | Human embryonic stem cell-derived endothelial cell product injection attenuates cardiac remodeling in myocardial infarction |
title_full | Human embryonic stem cell-derived endothelial cell product injection attenuates cardiac remodeling in myocardial infarction |
title_fullStr | Human embryonic stem cell-derived endothelial cell product injection attenuates cardiac remodeling in myocardial infarction |
title_full_unstemmed | Human embryonic stem cell-derived endothelial cell product injection attenuates cardiac remodeling in myocardial infarction |
title_short | Human embryonic stem cell-derived endothelial cell product injection attenuates cardiac remodeling in myocardial infarction |
title_sort | human embryonic stem cell-derived endothelial cell product injection attenuates cardiac remodeling in myocardial infarction |
topic | Cardiovascular Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9588936/ https://www.ncbi.nlm.nih.gov/pubmed/36299872 http://dx.doi.org/10.3389/fcvm.2022.953211 |
work_keys_str_mv | AT spiroskianamishel humanembryonicstemcellderivedendothelialcellproductinjectionattenuatescardiacremodelinginmyocardialinfarction AT mccrackenianr humanembryonicstemcellderivedendothelialcellproductinjectionattenuatescardiacremodelinginmyocardialinfarction AT thomsonadrian humanembryonicstemcellderivedendothelialcellproductinjectionattenuatescardiacremodelinginmyocardialinfarction AT magalhaespintomarlene humanembryonicstemcellderivedendothelialcellproductinjectionattenuatescardiacremodelinginmyocardialinfarction AT lalwanimukeshk humanembryonicstemcellderivedendothelialcellproductinjectionattenuatescardiacremodelinginmyocardialinfarction AT newtonkathrynj humanembryonicstemcellderivedendothelialcellproductinjectionattenuatescardiacremodelinginmyocardialinfarction AT millereileen humanembryonicstemcellderivedendothelialcellproductinjectionattenuatescardiacremodelinginmyocardialinfarction AT benezechcecile humanembryonicstemcellderivedendothelialcellproductinjectionattenuatescardiacremodelinginmyocardialinfarction AT hadokepatrick humanembryonicstemcellderivedendothelialcellproductinjectionattenuatescardiacremodelinginmyocardialinfarction AT brittanmairi humanembryonicstemcellderivedendothelialcellproductinjectionattenuatescardiacremodelinginmyocardialinfarction AT mountfordjoannec humanembryonicstemcellderivedendothelialcellproductinjectionattenuatescardiacremodelinginmyocardialinfarction AT beqqaliabdelaziz humanembryonicstemcellderivedendothelialcellproductinjectionattenuatescardiacremodelinginmyocardialinfarction AT graygilliana humanembryonicstemcellderivedendothelialcellproductinjectionattenuatescardiacremodelinginmyocardialinfarction AT bakerandrewh humanembryonicstemcellderivedendothelialcellproductinjectionattenuatescardiacremodelinginmyocardialinfarction |